Introduction
============

Schizophrenia is a severe, chronic, and disabling mental disorder affecting approximately 0.6% of the population worldwide ([@B77]). Among psychiatric disorders, it is considered the most disabling one, requiring a disproportionate share of mental health services ([@B87]). Individuals diagnosed with schizophrenia have impaired social and occupational functioning. Thus, schizophrenia is placed among the world's top leading causes of years lived with disability ([@B132]; [@B125]), being also the seventh most costly medical illness in our society ([@B32]).

The clinical features of schizophrenia are clustered in three categories: positive symptoms, negative symptoms and cognitive deficits. Positive or psychotic symptoms include delusions (false beliefs held with strong conviction in spite of contradictory evidence), hallucinations (perceptions in the absence of external stimulus, commonly experienced as hearing voices distinct from one's own thoughts), thought disorder (e.g., loose associations), and abnormal psychomotor activity (e.g., grossly disorganized behavior, posturing, or catatonia). Negative symptoms comprise social withdrawal, impairments in initiative and motivation, a reduced capacity to recognize and express emotional states and poverty in the amount or content of speech. Cognitive impairments include disturbances in selective attention, working memory, executive control, episodic memory, language comprehension, and social-emotional processing. Symptomatic onset occurs in late adolescence and early adulthood in males and somewhat later in females, who tend to be less severely affected ([@B1]). The course of schizophrenia is typically characterized by psychotic exacerbations or relapses alternating with periods of partial remissions.

The principal pharmacological treatment for schizophrenia is antipsychotic medication. In general terms, antipsychotic drugs are effective in reducing the severity of positive symptoms such as hallucinations and delusions and have made it possible for many individuals with schizophrenia to live outside hospital settings. Nevertheless, antipsychotics have minimal impact on both negative symptoms and cognitive impairments (see [@B79] for review). Thus, the treatment of schizophrenia with antipsychotics rarely, if ever, produces a cure or entirely reverses symptoms of the illness. Only 5--10% of persons with schizophrenia successfully achieve a full recovery with or without these medications. There is a good response to antipsychotic medication in 30--40% of patients. However, about 20% are resistant to standard antipsychotics and an additional 30--40% show an improvement but are residually symptomatic despite antipsychotic treatment ([@B113]).

The Glutamate Hypothesis of Schizophrenia
=========================================

Glutamate is the major excitatory neurotransmitter in the brain. It interacts with two types of receptors: (i) the ionotropic receptors, with NMDA, Kainate, and AMPA receptor subtypes connected to or representing ion channels, and (ii) the metabotropic glutamate receptors (mGluRs), which activate G protein-coupled signal transduction and comprising groups I to III with a total of eight identified subtypes ([@B88]).

The observation that the administration of phencyclidine (PCP) and the dissociative anesthetic ketamine ---two NMDA receptor antagonists--- could mimic schizophrenia symptoms in healthy individuals led to the hypothesis of a functional impairment of NMDA receptors in this disease ([@B57]; [@B97]; [@B119]). Importantly, it was described that NMDA receptor antagonists, besides inducing positive-like symptoms, also found to be induced by other stimulant drugs such as amphetamine and other dopaminergic agonists, were also able to evoke cognitive- and negative-like symptoms ([@B64]). Since dopamine release is under control of NMDA receptors in several brain circuits, some authors sustain that the glutamatergic dysfunction may be underlying the dopaminergic deficits found in schizophrenia ([@B56]).

Additionally, genome-wide association studies have shown that genes involved in glutamatergic neurotransmission and synaptic plasticity, e.g., mGluR3 (*GRM3*), glutamate ionotropic receptor NMDA type subunit 2A (*GRIN2A*), serine racemase (*SRR*), glutamate ionotropic receptor AMPA type subunit 1 (*GRIA1*) or neurogranin (*NRGN*), are associated with schizophrenia ([@B117]; [@B109]). Moreover, postmortem and neuroimaging studies have found that several components of glutamatergic signaling system are affected in schizophrenic patients ([@B37]; [@B118]; [@B20]). Thus, drugs targeted to restore the glutamatergic imbalance could provide better outcomes than those obtained with current antipsychotics in the treatment of schizophrenia. In this sense, preclinical and clinical studies have provided evidence for mGluRs 2, 3, and 5, muscarinic receptors M1 and M4 or the Glycine transporter GlyT1 among others as potential targets to retrieve the glutamatergic functioning in schizophrenia ([@B30]).

Group II Metabotropic Glutamate Receptors
=========================================

Genes encoding eight mGluR subtypes ---many of them with multiple splice variants--- have been identified and are classified into three groups (I--III) according to their sequence homology, coupling mechanism and pharmacology ([@B18]; [@B93]; **Figure [1](#F1){ref-type="fig"}**). Group II includes mGlu~2~ and mGlu~3~ receptors, that are coupled predominantly to G~i/o~ proteins, which mediate the downstream inhibition of adenylyl cyclase activity, modulation of voltage-dependent ion channels (inhibition of calcium and activation of potassium channels), and the regulation of other downstream signaling partners via released Gβγ subunits. Recent studies have shown that Group II mGluRs can also modulate additional signaling pathways, such as activation of PI3K and MAPK pathways ([@B55]; [@B93]; [@B91]).

![**Classification and sequence homology dendrogram of mGluRs.** The known splice variants and main signaling pathways are indicated. --AC, inhibition of adenylyl cyclase activity; +PLC, activation of phospholipase C.](fphar-07-00130-g001){#F1}

The mGlu~2~ and mGlu~3~ receptors share about 70% of their amino acid sequence ([@B100]). The gene encoding the human mGlu~2~R (*GRM2*) has been mapped to chromosome 3p21.1-p21.2 ([@B73]). For its part, mGlu~3~R gene (*GRM3*) was mapped to human chromosome 7q21.1-q21.2 ([@B108]). While no splicing variants have been reported for *GRM2*, alternative splicing has been described for *GRM3* leading to four different variants: full length mGlu~3~R, *GRM3*Δ*2* (lacking exon 2), *GRM3*Δ*4* (lacking exon 4), and *GRM3A2*Δ*3* (lacking exons 2 and 3); being the *GRM3*Δ*4* the most abundant one ([@B106]). Despite this variant lacks the transmembrane domain---which is encoded by exon 4--- it has been shown that it can be translated in cells, thus suggesting its potential function as a unique glutamate receptor ([@B93]).

Group II mGluRs are widely expressed throughout the central nervous system. The expression levels are moderate to high in different brain regions such as the prefrontal cortex (PFC), the dorsal and ventral striatum, the thalamus, the hippocampus, and the amygdala ([@B99]; [@B133]; [@B46]); regions that have been shown to be involved in cognition and emotional states. The mGlu~3~Rs expression across these regions is more disperse than that of mGlu~2~Rs ([@B95]; [@B46]). In the PFC mGlu~2~Rs present a high but restricted expression with a bilaminar distribution in layer I and layer Va while mGlu~3~Rs distribution is more homogenous throughout the cortex with a slight higher expression in layers I--III than in layers IV--VI ([@B71]). At the neuronal level, mGlu~2~Rs are localized at the perisynapse ([@B12]) mainly acting as autoreceptors where they function as a feedback negative mechanism to suppress the excessive glutamate release keeping the homeostasis of the synapse ([@B12]; [@B110]). However, both presynaptic and postsynaptic cortical immunoreactivity of mGlu~2~Rs has been described. For its part mGlu~3~Rs immunoreactivity has been shown mainly presynaptic ([@B90]; [@B94]; [@B121]) and whereas mGlu~2~Rs expression is restricted to neurons, mGlu~3~Rs are also found on glial cells ([@B95]; [@B121]) where they may interact with glutamate transporters ([@B5]).

Besides modulation of glutamate physiology, Group II mGluRs, also control the neurotransmitter release of other systems acting as heteroreceptors in GABAergic, dopaminergic, noradrenergic, or serotonergic synapses ([@B12]).

A limited number of molecules possess agonist activity across all mGluRs. The endogenous agonist [L]{.smallcaps}-glutamate, [L]{.smallcaps}-CCG-I \[(2S,10 S,20 S)-2-(carboxycyclopropyl)glycine\] and ABHxD-I (2-aminobicyclo\[2.1.1\]hexane-2,5-dicarboxylic acid-I) are the most potent ([@B2]). More recently, systemically active and highly selective agonists of Group II mGluRs have been developed, providing valuable insights into the *in vitro* and *in vivo* functions of these receptors ([@B93]). LY354740 ((1S,2S,5R,6S)-2-Aminobicyclo\[3.1.0\]hexane-2, 6-di carboxylic acid) was the first Group II mGluR selective agonist reported to exhibit a nanomolar affinity ([@B81]). It has been followed by more recent compounds, including LY379268 ((1S,2R,5R,6R)-2-amino-4-oxabicyclo\[3.1.0\]hexane-2,6-dicarboxylic acid), now a commonly used tool for studies of Group II mGluR function ([@B111]). These compounds are highly selective for Group II mGluRs relative to other mGluR subtypes but do not differentiate between mGlu~2~R and mGlu~3~R. Other Group II selective agonists have been described with submicromolar affinity, including (2R,4R)-APDC ((2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate) and DCG-IV ((2S,2′R,3′R)-2-(2′,3′-dicarboxycyclopropyl)glycine). Additiona lly, an analog of LY354740 with a methyl substituent at the C4α-position was reported to have mGlu~2~R agonist and mGlu~3~R antagonist activity ([@B22]). Thus far, no orthosteric antagonists have been discovered that are entirely specific for Group II mGluRs. However, LY341495 ((2S)-2-amino-2-\[(1S,2S)-2-carboxycycloprop-1-yl\]-3-(xanth-9-yl) propanoic acid) provides relatively high selectivity with nanomolar potency as a Group II mGluR antagonist with submicromolar to micromolar potencies at all other mGluR subtypes ([@B111]).

To date, besides orthosteric ligands, multiple selective positive allosteric modulators (PAMs) of mGlu~2~R have been identified. The majority are structurally related to either LY487379 (2,2,2-trifluoro-N-\[4-(2-methoxyphenoxy)phenyl\]-N-(3-pyridinylmethyl)ethanesulfonamide hydrochloride) or BINA (biphenyl-indanone A), two prototypical mGlu~2~R PAMs ([@B17]; [@B93]). Many of these compounds are highly selective for mGlu~2~R and do not potentiate responses to activation of mGlu~3~R or any other mGluR subtype ([@B16]). In addition, group II mGluR negative allosteric modulators (NAMs) have also been developed, but in this case acting at both mGlu~2~R and mGlu~3~R ([@B50]; [@B129],[@B130]).

Alterations of Group II mGluRs in Schizophrenia
===============================================

Postmortem Brain Studies
------------------------

Different approaches have been used to determine the possible alterations of both, mRNA and protein expression, of Group II mGluRs in the postmortem brain of schizophrenic subjects. The majority of the findings suggest that the level of expression of *GRM3* mRNA is unaffected in schizophrenia ([@B96]; [@B102]; [@B25]; [@B9]; [@B39]; [@B42]). Fewer studies have investigated *GRM2* mRNA expression in postmortem human brain of schizophrenic subjects. Semi-quantitative approaches such as *in situ* hybridization have reported unaffected levels of *GRM2* mRNA in thalamus ([@B102]), and higher *GRM2* mRNA expression in the PFC white matter ([@B39]). However, quantitative real-time PCR assays showed lower level of expression of *GRM2* mRNA in the PFC ([@B42]) and cerebellum ([@B9]) of schizophrenic subjects.

Studies using immunolabeling techniques have reported different outcomes in regard to Group II mGluRs protein expression levels in schizophrenia. Differentiation of mGlu~3~R from mGlu~2~R has been problematic because of the lack of selective ligands and antibodies. An early study, using non-specific antibodies that detect both mGlu~2~ and mGlu~3~ receptor proteins, found no change in mGlu~2/3~R expression in the PFC (BA46) of schizophrenic subjects compared to controls ([@B21]). A second study, using also non-specific antibodies, found a significant increase in mGlu~2/3~R expression in the BA46 of schizophrenic subjects compared to controls, but not in other cortical regions including BA9 and BA11 ([@B47]). The availability of specific antibodies allowed the evaluation of the protein expression of each subtype of Group II mGluRs. [@B19] found a significant decrease in the dimeric form of mGlu~3~Rs in the PFC (BA10) of schizophrenic subjects compared to controls, with unaffected levels of the monomeric forms. Similarly, another study reported a decrease in mGlu~3~R protein in the PFC (BA46) of schizophrenic subjects, but not in other areas such as temporal or motor cortices ([@B40]). This study reported unchanged mGlu~2~R protein expression in schizophrenia ([@B40]), however, the antibody used to assess the mGlu~2~R immunoreactivity was not previously validated and was actually measuring the subtype 2 of the AMPA ionotropic glutamate receptor ^[1](#fn01){ref-type="fn"}^.

Four independent studies have investigated the radioligand binding density of mGlu~2/3~Rs in the postmortem brain of schizophrenic subjects. [@B42], reported a decrease in the binding density of mGlu~2/3~Rs in the PFC (BA9) of schizophrenic subjects respect to matched controls using the mGlu~2/3~R antagonist \[^3^H\]LY341495. Other studies, however, reported no differences in mGlu~2/3~R binding density in the PFC (BA46) between schizophrenic subjects and controls when using either the mGlu~2/3~R agonist \[^3^H\]LY354740 ([@B31]) or the antagonist \[^3^H\]LY341495 ([@B78]). Two studies have evaluated the mGlu~2/3~Rs density in other areas besides PFC, founding no differences between schizophrenia and control groups neither in the anterior cingulated cortex (BA24; [@B76]; [@B78]) nor in the visual cortex (BA17; [@B78]).

Taking into account the different findings from postmortem studies the status of Group II mGluRs in schizophrenia remains unclear. Thus, further investigation of the level of expression and function of mGlu~2/3~Rs in postmortem human brain of schizophrenic subjects and controls is needed.

Genetic Studies
---------------

While other factors besides genetics are definitely involved, investigation of the genetic alterations responsible for schizophrenia represents a useful approach to better understand the cause of the disease ([@B49]). As mentioned above, mGlu~2~R gen (*GRM2*) has been mapped to chromosome 3p21.1--p21.2 ([@B73]), and linkage studies of schizophrenia show no positive results regarding this region ([@B86]). Moreover, in a population-based genetic study for candidate polymorphisms in alleles of the mGlu~2~R gene, no association was found between such polymorphisms and schizophrenia ([@B60]).

Genetic association analyses have consistently suggested an association between SNPs in the mGlu~3~R gene (*GRM3*) and schizophrenia ([@B34]; [@B25]; [@B14]; [@B107]; [@B15]) including a recent multi-stage schizophrenia genome-wide association study ([@B109]). However, this association was not replicated in other population-based genetic studies ([@B74]; [@B122]). *GRM3* polymorphisms associated with schizophrenia are often located in a non-coding region. Therefore, the mechanism underlying the association between *GRM3* and schizophrenia is not clear. *GRM3* polymorphisms have been associated with negative symptom improvement during olanzapine treatment ([@B8]). [@B25] proposed a specific pathway by which *GRM3* genotype could alter the glutamatergic transmission leading to an increase in the risk for schizophrenia. These authors found an association between an intronic variation in *GRM3* and a reduced performance on cognitive tests of prefrontal and hippocampal function, which are schizophrenia related phenotypes. Moreover, in postmortem human PFC, *GRM3* variant carriers showed lower mRNA levels of the glial glutamate transporter EAAT2. Therefore, authors suggest that the pathophysiological mechanism underlying schizophrenia may involve altered mGlu3 transcription/expression and altered glutamate neurotransmission related to a reduced expression of the glial glutamate transporter EAAT2 ([@B25]).

Group II mGluRs As Targets for Novel Antipsychotic Drugs
========================================================

Metabotropic glutamate receptors have received significant interest as potential drug targets. Such interest is due to the belief that metabotropic receptor targeting provides a way for modulating glutamate tone and phasic release in a more subtle manner than that which can be achieved through glutamate ionotropic receptors. Specifically, emerging preclinical and clinical data suggest that activation of Group II mGluRs is a mechanistically novel and promising approach for the treatment of schizophrenia ([@B70]; [@B48]; [@B63]; [@B114]; [@B17]; [@B13]; [@B27]; [@B124]; [@B127]).

Preclinical Evidences of Antipsychotic Activity
-----------------------------------------------

Extensive preclinical data proved that orthosteric Group II mGluR agonists, including LY354740, LY379268, and LY404039 exhibit antipsychotic-like properties in animal models of schizophrenia. The dissociative drugs PCP and ketamine have been shown to increase the activity of glutamatergic synapses in the PFC ([@B3]; [@B69]) and different studies have confirmed that Group II mGluR agonists are able to reverse this effect ([@B80]; [@B72]; [@B69]). It has been also shown that the systemic administration of the mGlu~2/3~R agonists LY379268 and LY404039 is able to increase dopamine extracellular levels in rodent's frontal cortex ([@B11]; [@B104]). Increases in cortical dopamine levels have been linked to the improvement of negative symptoms in schizophrenia. Additionally, atypical antipsychotic drugs such as clozapine and risperidone also produce a cortical increase of this neurotransmitter ([@B11]). Besides dopamine, cortical serotonin is also enhanced by the systemic administration of mGlu~2/3~R agonists as well as by the atypical antipsychotic risperidone ([@B11]; [@B104]). These neurochemical similarities between mGlu~2/3~R agonists and already known antipsychotic drugs provide support for the potential antipsychotic properties of the firsts.

In addition to this neurochemical evidence, Group II mGluR agonists have also shown the ability to reverse the behavioral effects induced by psychotomimetic drugs in several animal models predicting their potential as antipsychotic agents ([@B127]). In this sense, locomotor response to psychostimulants in rodents represents an animal correlate of schizophrenia positive symptoms ([@B4]). Regarding this aspect, the mGlu~2/3~R agonist LY354740 administered at a dose that did not affect spontaneous locomotor activity itself has proved to attenuate PCP-induced locomotor hyperactivity and stereotypies ([@B80]). Similar results have been reported with other mGlu~2/3~R agonists, like LY404039 ([@B103],[@B104]), LY379268 ([@B10]), MGS0008 and MGS0028 ([@B89]). Moreover, the hyperactivity induced by amphetamine has also been shown to be inhibited by both LY379268 and LY404039 ([@B35]; [@B103],[@B104]). Furthermore, the agonists MGS0008, MGS0028, and LY404039 have been reported to inhibit conditioned avoidance responses ([@B120]; [@B104]) and LY354740 has also shown ability to prevent the PCP-induced deficits on a working memory task ([@B80]), a paradigm that correlates with the cognitive dimension of schizophrenia symptoms ([@B4]). Interestingly, Group II mGluR agonists have also been shown to reverse the effects induced by 5-HT~2A~R hallucinogenic agonists. Thus, mGlu~2/3~R orthosteric agonists, such as LY379268 and LY354740, reduce the cellular ([@B134]; [@B42]), electrophysiological ([@B72]) and behavioral ([@B38]; [@B42]) effects induced by the hallucinogen 2,5-Dimethoxy-4-iodoamphetamine (DOI). Similar findings have been reported for the selective mGlu~2~R positive allosteric modulator (PAM) BINA ([@B7]). In fact, in recent years, more attention has been paid to mGluRs PAMs, especially to those selective for mGlu~2~R subtype ([@B26]). In this sense, several preclinical studies have shown efficacy for selective mGlu~2~R PAMs, i.e., CBiPES, JNJ-40411813, JNJ-42153605, and TASP0433864, in reversing psychotic-like symptoms ([@B59]; [@B52]; [@B51]; [@B66]). All of the above-mentioned findings support the potential use of mGlu~2/3~R agonists for the treatment of schizophrenia symptoms.

In regard to Group II mGluR agonists' selectivity, [@B112] have suggested that the antipsychotic effects of these compounds may be due to their affinity for D2 receptors ([@B112]). However, other laboratories have convincingly demonstrated that this direct effect of Group II mGluR agonists over dopamine receptors is not replicable ([@B28]; [@B135]). In terms of subtype selectivity, it has been suggested that the antipsychotic effects exerted by Group II mGluR agonists are mediated by mGlu~2~R rather than by mGlu~3~R ([@B131]; [@B27]; [@B124]). This hypothesis is based on the results obtained in studies performed with mGlu~2~R-KO and mGlu~3~R-KO mice. Thus, antipsychotic actions of Group II agonists LY404039 and LY314582 (racemic mixture of LY354740) were absent in mGlu~2~R-KO mice but present in mGlu~3~R-KO mice, strongly implicating mGlu~2~R as the predominant player in this effect ([@B115]; [@B29]). Similar results were observed for the Group II agonist LY379268 that reversed PCP- and amphetamine-evoked hyperactivity in wild type and mGlu~3~R-KO mice but not in mGlu~2~R-KO mice ([@B131]). This finding is further supported by the results observed with selective mGlu~2~R PAMs mentioned above, which have shown efficacy in animal behavioral paradigms used to assess the antipsychotic activity regarding both positive-like symptoms and cognitive impairments ([@B58]; [@B35], [@B36], [@B45]; [@B59]; [@B101]; [@B7]; [@B24]; [@B52]; [@B51]; [@B66]). The action of PAMs depends on the presence of a threshold level of agonist, since they do not activate the receptor directly. Hence, it has been postulated that PAMs may provide a safer and better tolerated therapeutic profile than orthosteric compounds, with a more regulated action and a lower potential receptor desensitization ([@B59]; [@B123]). On the other hand, mGlu~3~Rs have been recently postulated as potential targets to treat the cognitive dysfunction in schizophrenia. [@B126] showed that mGlu~3~Rs can influence synaptic plasticity within mice PFC and that the specific blockade of this receptor impairs learning in a mPFC-dependent fear extinction task. Thus, these authors propose selective PAMs of mGlu3Rs as a novel therapeutic strategy for enhancing prefrontal function in schizophrenic patients ([@B126]).

Clinical Evidences of Antipsychotic Activity
--------------------------------------------

The selective Group II mGluR agonists have been well-characterized and optimized and have entered into clinical trials for treatment of schizophrenia. The oral prodrug of LY404039, (1R,4S,5S,6S)-2-thiabicyclo\[3.1.0\]- hexane-4,6-dicarboxylic acid,4-\[(2S)-2-amino-4-(methylthio)-1-oxobutyl\]amino-, 2,2-dioxide monohydrate (LY2140023) developed by Eli Lilly and Co, showed significant antipsychotic efficacy for both positive and negative symptoms with no major side effects in a trial involving patients suffering from schizophrenia and also showed a better metabolic profile than the comparator olanzapine ([@B98]). Unfortunately, in the follow-up study, neither LY2140023 nor the comparator olanzapine were more efficacious than placebo as measured by the Positive and Negative Syndrome Scale (PANSS) total score due to higher-than expected placebo response ([@B62]), thus, the results of this study were considered to be inconclusive ([@B62]). In a more recent multicenter, randomized, double-blind, phase II study, LY2140023 monohydrate was again tested against placebo and the active control risperidone in schizophrenic patients with an acute exacerbation of symptoms. The primary outcome assessed change from baseline in the PANSS total score in an overall schizophrenia population and a predefined subpopulation which excluded non-Hispanic white patients with the A/A genotype at the serotonin 2A receptor (5-HT~2A~R) single nucleotide polymorphism rs7330461 ([@B23]). Neither LY2140023 dose showed significant improvement compared to placebo in either population. Conversely, risperidone showed a better efficacy than placebo in both populations ([@B23]). Finally, another study found no benefit of adjunctive treatment with LY2140023 versus placebo for negative symptoms in patients with schizophrenia receiving treatment with second-generation antipsychotics ([@B116]). The mGlu~2~R PAM JNJ-40411813/ADX71149 from Janssen Pharmaceuticals, Inc. and Addex Therapeutics has also been evaluated in clinical trials for schizophrenia treatment. Data reported in 2012 showed that JNJ-40411813/ADX71149 met the primary objectives of safety and tolerability and demonstrated an effect in patients with residual negative symptoms ([@B54]). The latest data in two phase-1 studies showed efficacy of the drug reducing the continuity of attention score, improving the quality of episodic memory and reducing the ketamine-induced negative symptoms in healthy volunteers ([@B105]). Another mGlu~2~R PAM that has advanced into clinical trials is the AZD8529 from AstraZeneca. Despite this compound failed to be effective in a phase 2 study when administered as monotherapy at a single dose in schizophrenic patients, it remains to be determined whether different treatment regimens or adjunct treatment would provide benefit ([@B67]).

The Role of the 5-Ht~2A~R/mGlu~2~R Heterocomplex
================================================

5-HT~2A~R and mGlu~2~R have been both implicated in the pathophysiology of schizophrenia and also have been considered as targets for antipsychotic drug development. Previous electrophysiological ([@B72]), cellular ([@B7]), neurochemical ([@B75]), and behavioral ([@B38]) data have suggested an interaction between 5-HT~2A~ and mGlu~2~ receptors. At present, it has been convincingly proved the existence of a specific functional heteromeric complex formed by 5-HT~2A~ and mGlu~2~ receptors through which serotonin and glutamate ligands modulate the pattern of G protein-coupling in living cells ([@B42]; [@B85]; [@B6]).

This serotonin-glutamate heterocomplex has been involved in the mechanism of action of both hallucinogenic ([@B44], [@B43]; [@B82]) and antipsychotic drugs ([@B33]). Thus, it has been reported that mGlu~2~R is necessary for at least some of the cellular and behavioral responses induced by hallucinogenic 5-HT~2A~R agonists such as lysergic acid diethylamide (LSD). It has been shown in \[^35^S\]GTPγS binding assays followed by immunoprecipitation with anti-G~q/11~ or anti-G~i1,2,3~ antibodies that the hallucinogenic 5-HT~2A~R agonist DOI activates both G~q/11~ and G~i~ proteins only when the 5-HT~2A~R is expressed as a receptor heterocomplex with the mGlu~2~R ([@B42]). Moreover, the head-twitch response was not produced by the hallucinogens DOI and LSD in mGlu~2~R-KO mice ([@B82]). Furthermore, it has been recently proved that the disruption of heteromeric expression with mGlu~2~R attenuates the psychosis-like effects induced in mice by hallucinogenic 5-HT~2A~R agonists ([@B85]; **Figure [2](#F2){ref-type="fig"}**). These authors, not only validate the 5-HT~2A~/mGlu~2~ receptor heterocomplex as necessary for the behavioral effects induced by LSD-like drugs in rodents, but also provide the first evidence for the specific residues responsible for a G protein-coupled receptor (GPCR) heteromeric complex formation ([@B85]).

![**G protein-dependent signaling and behavioral responses that require the 5-HT~2A~R/mGlu~2~R heterocomplex.** LSD acting at the 5-HT~2A~R/mGlu~2~R heterocomplex activates both G~q/11~- and G~i/o~-dependent signaling. In contrast, when 5-HT~2A~R and mGlu~2~R are prevented from forming a receptor heterocomplex, activation of 5-HT~2A~R by LSD elicits characteristic signaling of G~q/11~-protein subtypes. Head-twitch behavior is reliably and robustly elicited by hallucinogenic 5-HT~2A~R agonists, and is absent in mGlu~2~R-KO mice. Adapted from [@B41].](fphar-07-00130-g002){#F2}

Atypical antipsychotic drugs, such as clozapine and risperidone, have a high affinity for the serotonin 5-HT~2A~R, which preferred signaling pathway is via G~q/11~ proteins. Closely related non-antipsychotic drugs, such as ritanserin and methysergide, also block 5-HT~2A~R function, but they lack comparable neuropsychological effects. In this regard, it has been reported that these ligands inputs are actually integrated by the 5-HT~2A~R/mGlu~2~R heterocomplex that modulates signaling outputs and behavioral changes ([@B33]). Thus, serotonergic and glutamatergic drugs would bind to the 5-HT~2A~R/mGlu~2~R heterocomplex, which then balances G~i/o~- and G~q/11~-dependent signaling. The authors also state that 5-HT~2A~R/mGlu~2~R -mediated changes in G~i/o~ and G~q/11~ activity could predict the psychoactive behavioral effects of different pharmacological compounds.

Importantly, it has been demonstrated a dysregulation in the binding density of the receptors comprising this heterocomplex in postmortem PFC of schizophrenic subjects ([@B42]). Thus, increased 5-HT~2A~R and decreased mGlu~2/3~R binding was found in schizophrenic subjects compared to matched controls ([@B42]). Interestingly, 5-HT~2A~R density was comparable to control values in those subjects that were under antipsychotic treatment at time of death, whereas mGlu~2/3~R density remains decreased. Furthermore, the ligand binding interaction between the components of the 5-HT~2A~/mGlu~2~ receptor heterocomplex was found up-regulated in the postmortem PFC of schizophrenic subjects as compared with controls ([@B85]). Additionally, at the level of signaling, a recent study by same authors showed that mGlu~2~R-dependent activation of G~q/11~, but not G~i/o~ proteins, is reduced in the postmortem PFC from schizophrenic patients ([@B84]). Moreover, recent studies have reported altered densities and behavioral functions of 5-HT~2A~ and mGlu~2~ receptors in different animal models that resemble some aspects of schizophrenia. Thus, in frontal cortex of mice born to influenza virus-infected mothers, stressed mothers or lipopolysaccharide (LPS)-treated mothers the 5-HT~2A~R is upregulated ([@B83]; [@B53]; [@B128]) and the mGlu~2~R receptor is downregulated ([@B83]; [@B53]). Furthermore, these changes are translated into behavioral alterations, since increased head-twitch response to the hallucinogenic 5-HT~2A~R agonist DOI and decreased mGlu~2~-dependent antipsychotic-like effect of the mGlu~2/3~ agonist LY379268 were observed in these three studies ([@B83]; [@B53]; [@B128]).

A pharmacogenetic analysis of the efficacy of LY2140023 monohydrate in the treatment of schizophrenia has demonstrated a genetic association between several single nucleotide polymorphisms located in the gene encoding the 5-HT~2A~R and the response to LY2140023 treatment ([@B68]). Thus, a 30-point PANSS total reduction was seen in schizophrenic patients in the most responsive genotype group that presented the single nucleotide polymorphism rs7330461 for the 5-HT~2A~R gene ([@B68]). Additionally, a recent study has confirmed that the T/T genotype at rs7330461 is consistently associated with an increased treatment response to pomaglumetad methionil (LY2140023) compared to the A/A genotype ([@B92]).

All these facts point to a putative role of the 5-HT~2A~R/mGlu~2~R heterocomplex in the antipsychotic-like properties of the Group II mGluR agonists that could also explain the controversial results reported in clinical trials. In this way, it has been demonstrated that chronic atypical antipsychotics downregulate the transcription of mGlu~2~R through epigenetic modifications ([@B65]). This change occurs in concert with a 5-HT~2A~R-dependent up-regulation and increased binding of histone deacetylase 2 to the *mGlu2* promoter ([@B65]). This decrease in the mGlu~2~R expression could induce a lower response to Group II mGluR agonists as LY2140023 in patients previously treated with atypical antipsychotics. Accordingly, a recent study has reanalyzed previous clinical data on LY2140023 treatment defining two patients subpopulations based upon medication exposure during the 2 years before study entry ([@B61]). This analysis has demonstrated that patients previously treated with antipsychotics with prominent dopamine 2 receptor antagonist activity who were subsequently treated with LY2140023 monohydrate showed a significantly greater improvement on the PANSS total score from baseline than placebo treated patients. Conversely, patients previously treated with antipsychotics with prominent 5-HT~2A~R antagonist activity demonstrated no greater response than placebo ([@B61]). Thus, as LY2140023 monohydrate treatment is targeted to mGlu~2~R receptor activation it will induce lower efficacy if the mGlu~2~R receptor levels are reduced as a consequence of previous treatment with atypical antipsychotics.

Conclusion and Future Directions
================================

Several studies have showed that Group II mGluR agonists exhibit antipsychotic-like properties in preclinical assays. However, when these compounds have been used in human clinical trials the results have been controversial. Recent data suggest that this apparent lack of efficacy in schizophrenic patients may be related to previous exposure to atypical antipsychotics. Moreover, pharmacogenetic assays have demonstrated the influence of genetic variants on response to Group II mGluR agonists in patients with schizophrenia. The fact that Group II mGluRs represent a new target for the treatment of schizophrenia supports the need for additional investigation to establish the real efficacy of these new compounds. Moreover, it is mandatory to clarify if specific subgroups of patients could obtain a greater benefit from using these new drugs.
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